Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
- PMID: 37748560
- DOI: 10.1016/j.phrs.2023.106938
Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Keywords: Adalimumab; Inflammatory bowel disease; Infliximab; Pediatric; Pharmacogenetics; Polymorphism.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
LinkOut - more resources
Full Text Sources